Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02429466
Other study ID # IUCRO-0508
Secondary ID 1502729080
Status Completed
Phase Phase 1
First received
Last updated
Start date April 27, 2015
Est. completion date February 13, 2019

Study information

Verified date September 2020
Source Indiana University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, single arm, Phase I dose escalation study in subjects with refractory germ cell tumor (rGCT). This phase I will evaluate the safety and efficacy of SGI-110 in combination with cisplatin in subjects with rGCT. The primary objective is to determine the maximum tolerated dose (MTD) of SGI-110 to be used prior to cisplatin. A total of 15 subjects will be enrolled in this study at the Indiana University Simon Cancer Center.


Description:

Primary Objective:

To assess the safety and toxicity of guadecitabine (SGI-110) plus cisplatin including the dose limiting toxicity (DLT) and to determine the Maximum tolerated dose (MTD)

Secondary Objective:

To assess the efficacy of guadecitabine (SGI-110) to resume sensitivity to cisplatin in refractory GCT

Correlative Objective:

To evaluate the pharmacodynamic activity of guadecitabine (SGI-110) Evaluate miRNA biomarkers in serum on day 1 of cycles 1-6

Intervention and Mode of Delivery: Guadecitabine (SGI-110) will be given subcutaneously, daily, 30 mg/m2 on days (1-5) followed by cisplatin 100mg/m2 on day 8 every 4 weeks.

Duration of Intervention and Evaluation:

Treatment will be continued for a maximum of 6 cycles or until disease progression or unacceptable toxicity whichever occurs first. Subjects who are responding to therapy without major toxicty would be allowed to continue on single agent guadecitabine (SGI-110) at the MTD after 4-6 cycles of the combination therapy until disease progression. Subjects will be followed after the last cycle every 2 months for the 1st year, and every 4 months thereafter until death (expected overall survival less than 12 months).


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date February 13, 2019
Est. primary completion date June 4, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. = 18 years old at the time of informed consent

2. Written informed consent and HIPAA authorization for release of personal health information.

3. Subjects who are willing and able to comply with the protocol and study procedures including willingness to undergo tumor biopsy for tumor cells before therapy at Cycle 1, Day 1, and Day 8 (before cisplatin dose) if this is clinically and safely feasible to do so.

4. Subjects with histologically or serologically confirmed diagnosis of recurrent germ cell tumor.

5. Subjects who have platinum-resistant disease. There is no limit on the number of prior treatment regimens.

6. Subjects must have had prior high dose chemotherapy (HDCT) treatment when indicated.

7. Subjects who have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or elevated Tumor markers (hCG or AFP).

Note: patients without measurable disease are allowed on the study as long as they have clearly rising tumor markers and they will be exempt from biopsy.

8. Subjects with ECOG performance status of 0-2.

9. Subjects must be at least 3 weeks from last chemotherapy.

10. Females of childbearing potential must not be pregnant or breast-feeding. Male and female patients of reproductive potential must agree to use two forms of highly effective contraception from the screening visit through 30 days after the last dose of study drug. Acceptable forms of effective contraception include:

- Oral, injected or implanted hormonal methods of contraception.

- Placement of an intrauterine device (IUD) or intrauterine system (IUS).

- Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.

- Male sterilization (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate).

- True abstinence: When this is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.] Pregnancy tests for females of childbearing potential are required; must be serum at screening and the post treatment safety assessment visit. A positive urine pregnancy test must be confirmed by a serum pregnancy test and a pelvic US since some NSGCT may secrete beta-hCG and cause a false positive pregnancy. A pelvic US does not need to be repeated with each cycle unless the treating physician thinks it is necessary to do so.

11. The following laboratory values must be obtained within 14 days prior to registration for protocol therapy.

- Absolute neutrophil count = 1500 cells/mm3

- Hemoglobin (Hgb) = 8 g/dL

- Platelets count = 100,000 cells/mm3

- Serum creatinine levels = 1.5 mg/dl and calculated (by Cockcroft-Gault formula) or measured creatinine clearance = 50 mL/min

- Bilirubin = 2 x ULN

- Aspartate aminotransferase (AST, SGOT) = 3 x ULN

- Alanine aminotransferase (ALT, SGPT) = 3 x ULN

Exclusion Criteria:

1. Active central nervous system (CNS) metastases. Subjects with neurological symptoms should undergo a head CT scan or brain MRI to exclude brain metastasis, at the discretion of the treating physician.

NOTE: A subject with prior brain metastasis may be considered if they have completed their treatment for brain metastasis, no longer require corticosteroids, and are asymptomatic.

2. Treatment with any investigational agent within 30 days prior to registration for protocol therapy.

3. Concurrent participation in a clinical trial which involves another investigational agent.

4. Subjects with Grade 2 or greater neuropathy.

5. Subjects with a life-threatening illness, medical condition or organ system dysfunction, or other reasons which, in the Investigator's opinion, could compromise the subject's safety, interfere with or compromise the integrity of the study outcomes including incomplete recovery from the acute effects from any prior anti-neoplastic therapy.

6. Pregnancy or breast-feeding.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Guadecitabine (SGI-110)
SGI-110 will be given subcutaneously, daily, 30 mg/m2 on days (1-5) followed by cisplatin 100mg/m2 on day 8 every 4 weeks.

Locations

Country Name City State
United States Indiana University Hospital Indianapolis Indiana
United States Indiana University Melvin and Bren Simon Cancer Center Indianapolis Indiana

Sponsors (1)

Lead Sponsor Collaborator
Nasser Hanna

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Pharmacodynamic activity of SGI-110 Blood collection to measure change in peripheral blood mononuclear cells (PBMCs), global DNA and selected genes, and expression of DNMT levels Day 8
Other Pharmacodynamic activity of SGI-110 Tumor tissue collection to measure change in global DNA and selected tumor genes, and expression of DNMT levels Day 8
Primary Dose limiting toxicity (DLT) of guadecitabine (SGI-110) plus cisplatin During chemotherapy (weeks 1-18)
Primary Maximum tolerated dose (MTD) of SGI-110 plus cisplatin During chemotherapy (weeks 1-18)
Secondary Objective response rate (ORR) To evaluate Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) Days 42, 84, 126, 159, and 220
Secondary Progression free survival (PFS) The investigators will look at the duration between starting the therapy until progression of disease of subjects on this study Days 42, 84, 126, 159, and 220
See also
  Status Clinical Trial Phase
Recruiting NCT00772694 - Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy Phase 2
Completed NCT00705094 - Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients N/A
Terminated NCT00531687 - Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer Phase 2
Completed NCT00216801 - Relationship of Ochratoxin A to Upper Urologic Cancers N/A
Terminated NCT00820287 - Identification of Predictive Markers for Testis Cancer in a Population of Men With High Risk N/A
Active, not recruiting NCT03142802 - Low-Dose CT - Stage I Testicular Cancer N/A
Recruiting NCT03232541 - The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting N/A
Completed NCT03557177 - Clinical Characterisation of the Vascular Effects of Cis-platinum Based Chemotherapy in Patients With Testicular Cancer
Active, not recruiting NCT01783145 - Shared Care Follow-up After Chemotherapy for Testicular Cancer
Recruiting NCT05611307 - Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
Completed NCT02573584 - Vascular Fingerprint Validation Study
Recruiting NCT05670938 - Follow-up After Surgery for Testicular Cancer
Recruiting NCT02994758 - Development of Diagnostics and Treatment of Urological Cancers N/A
Completed NCT02991209 - Study of Testosterone vs Placebo in Testicular Cancer Survivors Phase 2/Phase 3
Completed NCT02602041 - Knowledge and Attitudes Regarding Healthy Lifestyle and Health Behavior Change in Cancer Patients and Their Partners; A Pilot Study
Completed NCT02092740 - REtrospective Study of TESTIcular CAncer Patients at the University Magdeburg N/A
Completed NCT01482741 - Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging N/A
Active, not recruiting NCT01242072 - Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies Phase 1
Completed NCT01242631 - Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer Phase 2
Completed NCT01135849 - B-Receptor Signaling in Cardiomyopathy N/A